Diagnosis and Management of Hypophosphatasia: Improving Patient Outcomes

Saturday, April 1, 2017
6:30 – 9:30 pm 
Hyatt Regency Orlando- Regency Ballroom R 
This activity is supported by an educational grant from Alexion Pharmaceuticals.

CLICK "BEGIN" TO EVALUATE SESSIONS, CLAIM CME, AND PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION.

Download Program Materials

Target Audience

Target audience: 

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, and other healthcare professionals caring for patients with metabolic bone disorders.

Learning Objectives

Learning objectives: 

Upon completion of this educational activity, learners will be better able to:

  • Describe the role of alkaline phosphatase and discuss the genetic underpinnings of hypophosphatasia
  • Describe the skeletal and non- skeletal manifestations of hypophosphatasia
  • Apply recently approved treatment option in perinatal, infantile and juvenile-onset hypophosphatasia
  • Management of ongoing treatment of patients with hypophosphatasia

Additional Information

AttachmentSize
ENDO 2017_Diagnosis and Managment of HPP_2.pdf2.81 MB
Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Bone and Calciotropic Hormones
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits™
  • 2.50 CME Certificate of Participation
Course opens: 
03/30/2017
Course expires: 
04/01/2018
Rating: 
No votes yet
0

Program Director

Leanne Ward, MD, FRCPC 
Associate Professor, Departments of Medicine and Surgery
University of Ottawa
Medical Director, Pediatric Bone Health Clinical and Research Programs
Children’s Hospital of Eastern Ontario
Ottawa, Canada
 
Faculty
Erik A. Imel, MD, MS
Assistant Professor of Medicine and Pediatrics
Indiana University School of Medicine
Indianapolis, IN
 
Linda A. DiMeglio, MD, MPH
Associate Professor of Pediatrics
Director of Career Development and Co-Chair of the Pediatric Protocol Development Team
Indiana University Clinical and Translational Science Institute
Indianapolis IN
 

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
 
Linda A. DiMeglio, MD: Investigator, Alexion
Leanne Ward, MD: Advisory Group Member, Alexion; Investigator, Novartis Pharmaceuticals
 
The faculty reported the no relevant financial relationship: Erik A. Imel, MD
 
The following SPC member who reviewed content for this activity reported relevant financial relationships:
 
E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Joan Han, MD: Research Support, Rhythm Pharmaceutical
 
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, Dexcom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Alan Kelly, MD: Speaker, Eli Lilly
Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
 
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
 
The following SPC members reported no relevant financial relationships: Connie Newman, MD, Amy Rothberg, MD
 
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships

Available Credit

  • 2.50 AMA PRA Category 1 Credits™
  • 2.50 CME Certificate of Participation

Accreditation Period

Course opens: 
03/30/2017
Course expires: 
04/01/2018